Metabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of β Cell Function
Authors' conclusion
The oral minimal model describes the differential metabolic phenotype of Stage 1 and Stage 2 T1D and identifies the φ total as a progression predictor. This supports its use as a sensitive tool and endpoint for T1D prevention trials.
Study context
- Population
- Individuals with islet autoimmunity screened at a TrialNet site, undergoing a 5-point, 2-hour oral glucose tolerance test (OGTT)
- Participants
- 27 vs 30
- Exposure
- Stage 2 vs Stage 1 T1D
- Stage 2n = 27
- Stage 1n = 30reference
- Outcome
- Metabolic phenotype (insulin secretion, sensitivity, clearance)
Main finding
As reported in the abstract
- Standard metrics of insulin secretion and sensitivity did not differ between Stage 1 and Stage 2 T1D
- Stage 2 vs Stage 1: P < 0.001
- Stage 2 vs Stage 1: P = 0.034
- Stage 2 vs Stage 1: P = 0.006
Observational data: associations, not effects.
Further findings
- Higher baseline φ total associated with reduced odds of disease progression, OR (interval)
- OR 0.92 [0.86, 0.98], P = .016
- Independent of stage
Original publication
Metabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of β Cell Function. J Clin Endocrinol Metab. Published 24 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →